Continuing its interest in antibody-drug conjugate (ADC) therapies, Genmab has agreed to pay US$4.5 M upfront and committed up to US$415 M more to gain exclusive access to Synaffix’s ADC platforms. The deal is currently for one undisclosed drug target, however, Genmab holds the option to develop further candidates for an unspecified number of additional targets. The technologies involved include antibody conjugation, linker-payloads and a polar spacer. The deal signifies Synaffix’s fifth out-licensing agreement since June 2021, as pharma and biotech companies become increasingly interested in the potential of its innovative platforms.